The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical relevance of miR-143 expression in ER-positive breast cancer patients.
 
Yoshihisa Tokumaru
No Relationships to Disclose
 
Masanori Oshi
No Relationships to Disclose
 
Eriko Katsuta
No Relationships to Disclose
 
Nobuhisa Matsuhashi
No Relationships to Disclose
 
Manabu Futamura
No Relationships to Disclose
 
Kazuhiro Yoshida
Honoraria - Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Johnson & Johnson; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Novartis; Olympus; Ono Pharmaceutical; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; SBI Pharmaceuticals; Taiho Pharmaceutical; Takeda; Teijin Pharma; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Abbvie (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Biogen (Inst); Celgene (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline K.K. (Inst); Johnson & Johnson (Inst); KCI (Inst); Koninklijke philips (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Meiji Seika Kaisha (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Kazuaki Takabe
No Relationships to Disclose